PA
ABOS icon

Perceptive Advisors’s Acumen Pharmaceuticals ABOS Stock Holding History

Perceptive Advisors’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-347,450
Closed -$1.88M – 100
2022
Q4 		$1.88M Sell
347,450
-52,550
-13% -$353K 0.05% 87
2022
Q3 		$4.01M Sell
400,000
-108,532
-21% -$623K 0.12% 88
2022
Q2 		$2.39M Sell
508,532
-88,410
-15% -$332K 0.07% 95
2022
Q1 		$2.33M Buy
+596,942
New +$3.25M 0.05% 118

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Perceptive Advisors's ABOS Position: Q1 2023 in Review

Perceptive Advisors sold out of Acumen Pharmaceuticals (ABOS) in Q1 2023, closing a stake of 347,450 shares — an estimated $1.88M sold.

Perceptive Advisors first reported a position in ABOS in Q1 2022 and held it in 4 quarters. The position peaked at $4.01M in Q3 2022. 61 funds tracked by Wall St. Rank hold ABOS as of Q1 2023.

  • Perceptive Advisors reported no remaining Acumen Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Perceptive Advisors sold 347,450 Acumen Pharmaceuticals shares in Q1 2023, an estimated $1.88M.
  • Perceptive Advisors first reported a position in Acumen Pharmaceuticals in Q1 2022 and held it in 4 quarters.
  • Perceptive Advisors's Acumen Pharmaceuticals position peaked at $4.01M in Q3 2022.
  • 61 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2023.

Based on Perceptive Advisors's 13F filing for Q1 2023, filed 15 May 2023.